TRAW
TRAW clinical trials: Traws Pharma, Inc.
Every trial on ClinicalTrials.gov where Traws Pharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 38
- Trials linked
- 35
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
TRAW on the catalyst calendar · TRAW registry changes
- Primary completion Feb 16, 2026ActualPhase 2NCT07157007Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19Traws Pharma, Inc. · COVID - 19CompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 1NCT07526506Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy VolunteersTraws Pharma, Inc. · Healthy VolunteerRecruitingTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT07371650This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate...Traws Pharma, Inc. · InfluenzaActive, not recruitingTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT07503405Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelTraws Pharma, Inc. · InfluenzaNot yet recruitingTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2025ActualPhase 1NCT06757738A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy VolunteersTraws Pharma, Inc. · Healthy Volunteer StudyCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2024ActualPhase 1NCT06402136Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy VolunteersTraws Pharma, Inc. · Healthy Volunteers OnlyCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2026Sponsor estimatePhase 1/Phase 2NCT05705505Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic MalignanciesTraws Pharma, Inc. · Endometrioid Endometrial CancerUnknown statusTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2024Sponsor estimatePhase 1NCT04739293Study of ON 123300 in Patients With Advanced CancerTraws Pharma, Inc. · Solid Tumors, AdultUnknown statusTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 26, 2020ActualPhase 3NCT02562443Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATraws Pharma, Inc. · Myelodysplastic SyndromeTerminatedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1NCT02168725Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid TumorsTraws Pharma, Inc. · NeoplasmsTerminatedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2020ActualPhase 1/Phase 2NCT01926587Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineTraws Pharma, Inc. · Myelodysplastic SyndromeCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2020ActualPhase 2NCT01904682Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsTraws Pharma, Inc. · Myelodysplastic SyndromesCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2019Sponsor estimatePhase 1NCT02075034Three Dosing Schedules of Oral Rigosertib in MDS PatientsTraws Pharma, Inc. · Myelodysplastic SyndromeWithdrawnTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2017ActualPhase 3NCT01928537Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineTraws Pharma, Inc. · Myelodysplastic SyndromesCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2018ActualPhase 3NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsTraws Pharma, Inc. · Myelodysplastic SyndromesCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 1NCT00854646Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)Traws Pharma, Inc. · Acute Myelocytic LeukemiaCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2014ActualPhase 1NCT02107235Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck CancerTraws Pharma, Inc. · Head and Neck NeoplasmsCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1NCT02030639Metabolism and Excretion of [14C]-Rigosertib After Infusion to VolunteersTraws Pharma, Inc. · HealthyCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT01807546Oral Rigosertib for Squamous Cell CarcinomaTraws Pharma, Inc. · Head and Neck Squamous Cell CarcinomaCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 2NCT01584531Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeTraws Pharma, Inc. · Myelodysplastic SyndromeCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2010ActualPhase 1NCT01538563Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced CancerTraws Pharma, Inc. · Solid TumorsCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2010ActualPhase 1NCT01538537Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced CancerTraws Pharma, Inc. · Advanced CancerCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1NCT01168011Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsTraws Pharma, Inc. · Solid TumorCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2013ActualPhase 1/Phase 2NCT01167166Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)Traws Pharma, Inc. · Acute Myelocytic LeukemiaCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2011ActualPhase 1NCT01165905Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsTraws Pharma, Inc. · Solid TumorCompletedTRAWLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 13 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner